Information  X 
Enter a valid email address

MaxCyte, Inc. (MXCT)

  Print      Mail a friend

Wednesday 19 December, 2018

MaxCyte, Inc.

Change of Auditor

RNS Number : 8667K
MaxCyte, Inc.
19 December 2018




MaxCyte, Inc.

("MaxCyte" or the "Company")


Change of Auditor


Gaithersburg, Maryland - 19 DECEMBER 2018: MaxCyte (LSE: MXCT), the global cell-based medicines and life sciences company, is pleased to announce that following the conclusion of a formal tender process overseen by the Company's audit committee, the Company has appointed CohnReznick LLP (which ranks among the largest accounting, tax and business advisory firms in the United States) as the Company's independent auditor for the financial year ended 31 December 2018. The appointment of CohnReznick LLP as the Company's auditor for the financial year ended 31 December 2019 will be subject to approval by the Company's shareholders at the next Annual General Meeting due to be held in October 2019.


Aronson LLC has confirmed to the Company that it is not aware of any circumstances connected with its termination as auditor that it considers should be brought to the attention of the Board, creditors or shareholders of the Company. MaxCyte would like to thank Aronson LLC for its many years of service to the Company.


About MaxCyte 

MaxCyte is a global cell-based medicines and life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for rapid autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer.  MaxCyte has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit


About CohnReznick 

CohnReznick LLP ranks among the largest accounting, tax and business advisory firms in the United States, with a team of over 2,400 professionals and an extensive footprint in 26 cities worldwide.



For further information, please contact:


MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer


+1 301 944 1660

Nominated Adviser and Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns



+44 (0)20 7886 2500

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji


+44 (0)203 709 5700

[email protected]



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t